JaLCDOI 10.18926/AMO/55305
FullText URL 71_4_291.pdf
Author Naganuma, Atsushi| Hoshino, Takashi| Suzuki, Yuhei| Uehara, Daisuke| Kudo, Tomohiro| Ishihara, Hiroshi| Sato, Ken| Kakizaki, Satoru| Yamada, Masanobu| Takagi, Hitoshi|
Abstract The effect of skeletal muscle mass (SMM) on the outcomes of sorafenib treatment for hepatocellular carcinoma (HCC) has not been established. We measured the SMM in HCC patients treated with sorafenib, evaluated the patients’ survival, and evaluated the association between skeletal muscle depletion and sorafenib treatment. Of the 97 HCC patients treated with sorafenib at our institution in the period from July 2009 to February 2015, our study included 69 patients (51 males, 18 females) who had received sorafenib for ≥ 8 weeks and whose follow-up data were available. SMM was calculated from computed tomography images at the mid-L3 level (cm2) and normalized to height (m2) to yield the L3 skeletal muscle index (L3-SMI, cm2/m2). The median L3-SMI value was higher in the males (43 cm2/m2) compared to the females (36 cm2/m2). In the males only, the multivariate Cox regression identified an L3-SMI <43 cm2/m2 as independently associated with higher mortality compared to an L3-SMI ≥43 cm2/m2 (hazard ratio 2.315, 95% confidence interval: 1.125-4.765, p=0.023). Skeletal muscle depletion is a factor predicting poor prognosis for male patients with advanced HCC treated with sorafenib.
Keywords skeletal muscle depletion hepatocellular carcinoma sorafenib L3 skeletal muscle index prognostic factor
Amo Type Original Article
Published Date 2017-08
Publication Title Acta Medica Okayama
Volume volume71
Issue issue4
Publisher Okayama University Medical School
Start Page 291
End Page 299
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28824184